Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).

Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML....

Full description

Bibliographic Details
Main Authors: Julie A Zorn, Qi Wang, Eric Fujimura, Tiago Barros, John Kuriyan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4383440?pdf=render

Similar Items

Similar Items